- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
- News News
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Reports 2020 State of the States Medical Cannabis Access for Pain Treatment Medical Cannabis in America Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit
- Join Join
In this issue:
- International Patient Coalition Seeks UN Action
- Advocates Urge Obama to Fire DEA Chief
- Senate Votes to Let VA Doctors Recommend
- Minnesota Adds Pain to Qualifying Conditions
- New York Enacts Emergency Measure
- Florida Selects Five Nurseries to Cultivate Cannabis
- More than 1,000 Apply for Maryland Licenses
- Rally in Pennsylvania Urges Lawmakers to Act
- Action Alert: Support the CARERS Act
International Patient Coalition Addresses World Health Organization
On November 16, ASA Executive Director Steph Sherer joined patient advocates representing 27 countries who travelled to Geneva to address the World Health Organization (WHO). They urged the WHO’s Expert Committee on Drug Dependence to reshape policies that affect the health and safety of millions of patients using cannabis and cannabis products worldwide. That committee is an important advisor to the United Nation’s Commission on Narcotic Drugs, which sets international drug policies. The United Nations General Assembly Special Session on Drugs (UNGASS 2016) is set for April 2016 in New York.
“The current international policies on cannabis are outdated and are having a detrimental impact on patients in the United States and worldwide,” says ASA’s Sherer, ASA executive director and a representative of the International Medical Cannabis Patients Coalition. “New policies should take into account new clinical research, product safety protocols and global patient needs.”
UNGASS 2016 was scheduled in September 2012 at the request of the presidents of Colombia, Guatemala and Mexico, co-sponsored by 95 other countries. The special session will include a review of the treaties that drive international drug policy: the Single Convention on Narcotic Drugs of 1961, the Convention on Psychotropic Substances of 1971, and the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988.
Today over two-thirds of the population of the United States live where medical cannabis is legal locally, and over 2.5 million Americans are using it under a doctor’s supervision. Canada, Israel, Netherlands, Czech Republic, Croatia, Mexico, Uruguay, Romania, Germany, Jamaica, Australia, and Switzerland all have national medical cannabis programs and dozens of other countries are reviewing legislation. These laws are all arguably in conflict with international treaties such as the UN Single Convention.
“This is the first time in our lifetime for science to trump ideology and pave the way for more consistent patient access to this medicine worldwide,” said Michael Krawitz, executive director of Veterans for Medical Cannabis Access.
The International Medical Cannabis Patient Coalition (IMCPC) was established in March this year at a conference in Prague, where representatives of medical cannabis patient organizations from 13 countries came together. Many countries that might fully integrate cannabis into medical treatment are constrained by UN treaties, creating conflicts and contradictions similar to those in the U.S.
“The French paradox of medical cannabis is giving patients hope but with no legal access this leads them to buy unsafe products on the black market,” said IMCPC representative Sébastien Béguerie, founder of l'Union Francophone pour les Cannabinoides en Médecines. “It is making medical cannabis patients criminals, suffering not only from their ailments, but also their illegal status.”
Advocates and Members of Congress Urge Firing of DEA Chief
Pressure is mounting on DEA Acting Administrator Chuck Rosenberg. On November 20, medical cannabis advocates delivered a petition with more than 100,000 signatures calling for his ouster. The petition was started a mere two weeks earlier, after Rosenberg publicly called medical cannabis “a joke.”
The petition was organized by Tom Angell of Marijuana Majority, whose mother is a patient, and was supported by Americans for Safe Access and other advocacy groups. Angell and other advocates held a press conference in front of DEA headquarters in Arlington, Virginia as they delivered the boxes of signatures.
Medical cannabis patients of all ages were present to deliver the petition, along with parents who testified to its life-saving properties for their children with intractable seizure disorders and veterans who rely on it to stave off the symptoms associated with their PTSD.
“There’s nothing funny about suicidal thoughts, and those are something my family and I lived with day-to-day die to my military-related PTSD,” said Navy veteran T.J. Thompson, who helped found the ASA chapter in Virginia. “Using medical marijuana not only helps with my condition, but it has also had the added effect of making me a better father and husband.”
Rosenberg had expressed his discomfort with the idea of patients finding therapeutic relief from cannabis, saying “don’t call it medicine — that is a joke.” That statement was not his first on cannabis since becoming acting head of the DEA. Shortly after he was named to the position, he admitted that he was “not an expert” on cannabis and could not say whether it is more or less dangerous than heroin. Rosenberg clarified his position a few weeks later, but the stage was set for the calls for his removal.
“We join the more than 100,000 concerned Americans who are urging President Obama to fire Chuck Rosenberg immediately and appoint someone who understands the science,” said Mike Liszewski, ASA Government Affairs Director. “With NIDA, the National Cancer Institute, and other federal agencies coming around to the medical value of cannabis, the DEA is one of the last bastions of Reefer Madness mentality.”
The petition followed on the heels of an angry Congressional letter to President Obama that condemned Rosenberg’s remarks for “trivializing” the issue. The bipartisan group of lawmakers urged the President to fire him because “[c]avalier statements like these fly in the face of state policy and the experience of millions of patients.”
Rep. Earl Blumenauer (D-OR), the lead author of the letter, also spoke out on the floor of the House. The other six members who signed the letter are Steve Cohen (D-TN), Sam Farr (D-CA), Ted Lieu (D-CA), Jim McDermott (D-WA) and Dana Rohrabacher (R-CA).
Despite hundreds of clinical studies and case reports that indicate the medical efficacy of cannabis, the federal government insists that this ancient botanical medicine satisfy the expensive, protracted large-scale clinical trials required to market new, synthetic pharmaceutical drugs. A recent report by the Brookings Institution details how cannabis faces unique barriers to that research, including the DEA-mandated NIDA-monopoly on research and its Schedule I status, which the DEA has stridently defended for decades.
Senate Votes to Let VA Doctors Recommend
The Department of Veterans Affairs may be forced to end its ban on their doctors providing the recommendations veterans need to participate in state medical cannabis programs. The day before Veterans Day, the Senate passed an amendment to the VA budget to allow it. The Daines/Merkley amendment to the FY2016 Military Construction and Veterans Affairs Appropriations Bill passed the Senate Appropriations Committee in May before moving to the Senate floor. The House narrowly rejected a similar measure in the spring, so the fate of the amendment hinges on how lawmakers reconcile the two versions of the VA budget bill.
The amendment would prevent the Justice Department from spending funds to restrict doctors or penalize veterans who use medical cannabis in states that allow it.
Minnesota Adds Pain to Qualifying Conditions
Minnesota officials last month opened up their medical cannabis program to patients suffering from intractable pain, the most common condition for which patients seek relief with cannabis.
Department of Health Commissioner Dr. Ed Ehlinger announced the decision, which he called the “right and compassionate choice,” and urged health care providers to do more to help patients manage pain.
“This gives new options for clinicians and new hope for suffering patients,” Ehlinger said in a statement. “With Minnesota’s cautious and well-designed program, we can safely and responsibly give patients and providers the option of adding medical cannabis as a tool to treat intractable pain.”
Beginning July 1, doctors will be able to certify intractable pain patients for Minnesota’s program. Certified patients will be able to access medical cannabis on August 1.
Originally, Minnesota’s medical cannabis program included only nine qualifying conditions, but the health commissioner was directed to evaluate other conditions to add, beginning with intractable pain.
Intractable pain is defined in the law as a condition “in which the cause of the pain cannot be removed or otherwise treated with the consent of the patient and in which, in the generally accepted course of medical practice, no relief or cure of the cause of the pain is possible, or none has been found after reasonable efforts.”
MDH on Medical Cannabis for Intractable Pain.
New York Enacts Emergency Measure
Governor Andrew Cuomo bowed to pressure in early November and signed an emergency measure designed to speed up the roll out of New York’s medical cannabis program. The move came less than two months before New York’s Compassionate Care Act of 2014 is scheduled to go into full effect.
Patient advocates and state lawmakers have been concerned by setbacks in the program’s implementation, prompting the legislature to pass a pair of bills (A. 7060, S. 5086) that create “an expedited pathway” for patients. The new law does not immediately put medicine in patients’ hands but allows special certification for legal use of cannabis by “patients for whom delay in the patient’s certified medical use of marihuana poses a serious risk to the patient’s life or health.” It also allows the Health Department to expedite registration of production and dispensing companies.
The five medical cannabis companies licensed by the state so far say most of the 20 dispensaries they are authorized to open will be serving qualified patients by the original law’s mid-January deadline.
Lawmakers are also concerned New York officials have not recruited enough physicians to complete the required four-hour course to issue recommendations, and the limited number of qualified patients will make medicine prices excessive. New York state officials will set retail prices for cannabis products based on reported production costs.
The sponsor of the Assembly bill, Richard Gottfried (D-Manhattan), said in a statement that the emergency action was needed because “for the most seriously ill patients, even minor delays — a day, a week, a month — are life-changing.”
Florida Selects Five Nurseries to Cultivate Cannabis
Florida state officials announced the five companies that will be licensed to produce medical cannabis for the CBD extracts that will be the only legally available products. The CBD extracts are supposed to be available to patients with seizure disorders and cancer by June 2016.
The five cultivators were selected from 28 applicants by a panel of three state reviewers, based on rules set by a panel that included representatives from five commercial nurseries.
The 2014 law originally established a lottery system, but that was changed in response to lobbying by state nurseries, leading to accusations of cronyism. To be considered, applicants had to have been in business in Florida for 30 years and growing at least 400,000 plants.
More than 1,000 Apply for Maryland Licenses
A flood of applicants for medical cannabis business licenses in Maryland have delayed the state’s decision. The Maryland Medical Cannabis Commission received more than 1,000 applications. The vast majority, 811, were from groups seeking to open dispensaries. Two will be granted for each of the state’s 47 senate district, but three of those districts had considerably more than 100 applicants apiece. Fifteen cultivation applicants will be selected from the 146 who have applied. Regulators will decide how many of the 124 processor applications to approve, but the law sets no limit.
Initial license approvals were expected by the start of 2016, but that will be delayed by the deluge of applicants.
Complicating matters is the resignation of the head of the commission responsible for licensing decisions. Hannah Byron, who has had the post for a year, announced she will step down as executive director of the Natalie M. LaPrade Maryland Medical Cannabis Commission on January 27.
Natalie M. LaPrade Maryland Medical Cannabis Commission
Rally in Pennsylvania Urges Lawmakers to Act
Medical cannabis advocates rallied in Pennsylvania on December 5 to urge state lawmakers to take immediate action on a bill that has been stalled in the House. The state Senate passed a medical cannabis bill in May.
The House Rules Committee voted to put the measure to a vote in mid-November, but the bill has been saddled with more than 100 restrictive amendments. Among them is a limit of 10% on THC content and a provision that would end the program after two years though it will take 18 months to get started.
Another amendment would create an advisory board for regulating the program that would include the state police commissioner and the presidents of the District Attorneys Association and the State Police Chiefs Association, who have publicly opposed the program, but only one patient.
Take action today! Tell your Senators and Representative they need to take comprehensive action on medical cannabis with the Compassionate Access, Research Expansion, and Respect States Act. The CARERS Act would resolve the conflicts between compassionate state laws and outdated federal policies. CARERS would also reschedule cannabis, permit VA doctors to discuss medical cannabis with veterans, and allow cannabis businesses to have bank accounts.
Sign the Petition to support the CARERS Act at SafeAccessNow.org/carers.
Get a printable version of this newsletter to distribute